News

Women with myasthenia gravis (MG) have a poorer quality of life than male patients. That’s the conclusion of a study named “Best Abstract Award” winner at the 2017 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting in Phoenix. Specifically, the study, which used Patient Registry data from the…

HanAll Biopharma and Harbour BioMed will develop two new medicines for the treatment of IgG-mediated autoimmune diseases, including myasthenia gravis (MG) and other inflammatory diseases. HanAll will receive $81 million, develop the drugs, and have the right to registration and sales milestones, as well as royalties on net sales.

The cost of Genentech’s myasthenia gravis treatment Rituxan (rituximab) is half that of the blood purification process known as plasmapheresis and a third that of intravenous immunoglobulin therapy over a patient’s lifetime, according to a study. Few health insurance systems reimburse the costs of Rituxan for myasthenia gravis, the researchers…

Soliris (eculizumab) continued improving myasthenia gravis patients’ muscle strength and functioning in a 52-week extension of a 26-week Phase 3 clinical trial, researchers reported. Alexion Pharmaceuticals said the extension study covered the same category of participant: patients with refractory generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AchR) antibodies. The original Phase 3 trial…

Catalyst Pharmaceuticals announced that it will soon begin a Phase 3 clinical trial to assess Firdapse (amifampridine phosphate) in people with myasthenia gravis who are positive for the MuSK antibody. In meetings, the company and the U.S. Food and Drug Administration (FDA) arrived at an agreement regarding the size, scope and objectives of…

Prograf (tacrolimus) moderately improves myasthenia gravis (MG) in patients with inadequate response to glucocorticoids (GCs), a new study from China shows. The study, “Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China,” appeared in the…

ARGX-113, an investigational therapy for myasthenia gravis (MG), is progressing in a Phase 2 clinical trial (NCT02965573) that is still enrolling patients, according to the biotech company argenx in its quarterly update. MG is an autoimmune disorder, mostly characterized by abnormal responses of the patients’ own T-cells (a type…

Accordant’s myasthenia gravis services program has been accredited by an organization that assesses whether providers meet standards for caring for people with rare diseases. The accreditation came from the National Committee for Quality Assurance, which also certified that Accordant met standards for caring for patients with several other rare diseases.

The European Commission (EC) has approved Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The approval of Soliris, marketed by Alexion Pharmaceuticals, follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…

Muscle regeneration in myasthenia gravis likely is delayed as a result of the impaired functioning of muscle stem cells, called satellite cells (SCs), a study has found. The study, “Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration,” was published in the journal Acta Neuropathologica.